Showing results (61-70 of 216) with videos related to

Sort By:
Pageof 22
Oncotargets and Therapy|March 7, 2017
Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancerJin Sheng, Wenfeng Fang, Xia Liu, et al.
Cancer Communications (London, England)|November 9, 2019
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)Zhonghan Zhang, Fan Luo, Yang Zhang, et al.
Drug Delivery|January 10, 2018
Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancerMeng Wu, Hongyun Zhao, Liang Guo, et al.
World Journal of Surgical Oncology|May 7, 2016
Inflammation-based prognostic system predicts postoperative survival of esophageal carcinoma patients with normal preoperative serum carcinoembryonic antigen and squamous cell carcinoma antigen levelsQilong Ma, Wengao Liu, Ran Jia, et al.
Clinical Lung Cancer|May 3, 2017
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head TrialsYaxiong Zhang, Zhonghan Zhang, Xiaodan Huang, et al.
Plos One|October 21, 2014
Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analysesWenhua Liang, Xuan Wu, Shaodong Hong, et al.
JAMA Network Open|October 19, 2020
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysisTing Zhou, Zhonghan Zhang, Fan Luo, et al.
BMC Medicine|August 27, 2025
Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trialYuanyuan Zhao, Yuxiang Ma, Tengrui Yin, et al.
Annals of Translational Medicine|January 13, 2021
Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancerTing Zhou, Lin Zhang, Tingting Liu, et al.
Iscience|June 16, 2025
Anti-OX40 antibody BAT6026 in patients with advanced solid tumors: A multi-center phase I studyHuaqiang Zhou, Yuxiang Ma, Yongsheng Li, et al.
Pageof 22